Business context and reporting period
The supplied filing is Organovo Holdings, Inc.’s unaudited Form 10-Q for the quarter ended December 31, 2014 (fiscal 2015 third quarter), not a filing identified as Vivosim Labs, Inc. Organovo develops and commercializes 3D human tissues for research, drug testing and potential therapeutic uses. In November 2014, it announced the full commercial release of exVive3D Human Liver Tissue. The company reported that it had not yet generated significant revenue from its planned principal operations.
Financial performance and condition
| Metric | Three months ended Dec. 31, 2014 | Three months ended Dec. 31, 2013 | Nine months ended Dec. 31, 2014 | Nine months ended Dec. 31, 2013 |
|---|---|---|---|---|
| Revenue | $155,000 | $135,000 | $304,000 | $264,000 |
| Operating expenses | $7.1 million | $4.8 million | $22.6 million | $14.2 million |
| Operating loss | $7.0 million | $4.6 million | $22.3 million | $14.0 million |
| Net loss | $7.0 million | $5.2 million | $22.3 million | $19.4 million |
| Net loss per share, basic and diluted | $0.09 | $0.07 | $0.28 | $0.27 |
Quarterly revenue increased 15%; nine-month revenue increased 15%. Product and service revenue was $139,000 in the quarter, primarily from initial exVive3D shipments and related research services. For the nine months, revenue was approximately flat in scale, while its source shifted toward the liver tissue product and services.
For the nine months, cash used in operating activities was $14.0 million, versus $10.2 million a year earlier; investing activities used $0.9 million versus $0.1 million. Financing provided $16.7 million versus $44.5 million, including $16.1 million of net proceeds from at-the-market stock sales. Cash and cash equivalents were $50.0 million at December 31, 2014, up from $48.2 million at March 31, 2014. Working capital was $46.8 million, compared with $47.3 million at March 31. Accumulated deficit was $114.5 million.
Total liabilities were $3.8 million, including $298,000 of warrant liabilities and $8,000 of current capital lease obligations; the filing reports no significant conventional debt balance. The company had $79,000 of restricted cash. No profit margin is meaningful given the small revenue base and continuing substantial losses.
Changes, outlook and risks
- Quarterly operating expenses rose 48% year over year; nine-month expenses rose 59%. Management attributed the increases mainly to expanded staffing, research and development, commercialization preparations, facility expansion, public-company costs and stock-based compensation.
- Research and development expense was $9.3 million for nine months, up 69%; R&D headcount increased from 26 to 49 year over year. General and administrative expense was $13.3 million, up 54%.
- Management said available cash and expected receipts should fund planned operations for at least the next 12 months, but stated that additional capital will be needed to further develop and commercialize its technology. Future equity financing could dilute shareholders; debt financing could impose payment obligations and restrictive covenants.
- Management expected post-launch revenue to be primarily from services and product sales, with revenue recognition generally several months after project work begins; typical projects were expected to last four to six months. The filing provides no quantified revenue or profitability guidance.
- Key risks include an early-stage business with limited commercial revenue and ongoing losses; uncertain customer acceptance, technical performance, regulation and commercialization; reliance on collaborations, grant funding and access to human cells; competition; and potential financing needs. The company reported no off-balance-sheet arrangements.
- The company is defending claims by Spencer Trask Ventures concerning fees and alleged confidentiality breaches. Arbitration was scheduled for July 2015; the company said it considered the claims without merit. It recorded no loss contingency because it had not determined an unfavorable outcome was probable or reasonably estimable.
- Disclosure controls were assessed as effective, and management reported no material change in internal control over financial reporting during the quarter.
Important facts for investors to verify
- Confirm the intended issuer: the provided filing is for Organovo Holdings, Inc., not Vivosim Labs, Inc.
- Track conversion of the exVive3D launch and research-service activity into recognized, recurring revenue, including customer acceptance and project timing.
- Assess cash burn against the stated at-least-12-month funding outlook and the company’s dependence on future capital raises.
- Review dilution from at-the-market offerings, outstanding options and warrants, and shares reserved under equity plans.
- Follow the Spencer Trask arbitration and any developments in regulatory, technical, customer-demand or commercialization risks.